Anna Schinzel

Anna Schinzel has a diverse work experience in the field of oncology and genomics.

Anna is currently working as the Associate Director of Oncology Discovery at Atavistik Bio since February 2022.

Prior to that, they worked at Kronos Bio, Inc. where they held the positions of Principal Scientist from January 2021 to February 2022 and Senior Scientist from February 2020 to January 2021.

From March 2017 to March 2020, they worked at Cedilla Therapeutics as a Senior Scientist.

Anna also worked as a Consultant at Third Rock Ventures from March 2017 to April 2018.

Before that, from October 2016 to August 2017, they worked as a Lab Member in the William Kaelin Lab at Dana Farber Cancer Institute.

Anna gained experience as an Analyst at Nextech Invest Ltd. from March 2016 to August 2016.

Additionally, they worked as an Associate Director at the Center for Cancer Precision Medicine at DFCI/Broad Institute/Brigham and Women's Hospital from an unspecified start date to November 2015. In this role, they were responsible for leading a team in genomic characterization and overseeing scientific projects.

Their career also includes a role as Co-Director of the Functional Genomics Screening Center at Dana Farber Cancer Institute/Harvard Cancer Center from an unspecified start date to 2014.

Anna began their career as a Post-Doctoral Fellow at the Broad Institute of MIT and Harvard/Dana Farber Cancer Institute/Harvard Medical School from January 2006 to an unspecified end date.

Anna also served as a Post-Doctoral Fellow at Dana-Farber Cancer Institute/Harvard Medical School from January 2004 to January 2006, where they conducted research on neuronal cell death and mitochondrial permeability.

Anna Schinzel has a diverse education history. Anna started by completing their International Baccalaureate at the International School of Geneva in Switzerland. Afterwards, they pursued a Bachelor of Science (BSc) and Master of Research (MRes) in Biochemistry at the University of Manchester in the United Kingdom from 1995 to 1999. Anna then went on to obtain their Doctor of Philosophy (PhD) at The University of Freiburg from 2000 to 2004, focusing on Biochemistry. Continuing their academic journey, they undertook a Post Doctoral Fellowship in Oncology and Cancer Biology at the Dana Farber Cancer Institute. Later on, they expanded their expertise by enrolling at the Harvard Extension School from 2013 to 2015, where they studied Finance, specifically Principals of Finance and Corporate Finance.